Avicanna Inc.

Equities

AVCN

CA05368K1003

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 11:20:18 2024-04-29 am EDT			5-day change	1st Jan Change
0.37 ^CAD	+2.78%		-2.63%	+5.71%

Apr. 19	Avicanna Raises About $2.1 Million in Non-brokered Private Placement	MT
Apr. 18	Avicanna Inc. announced that it has received CAD 2.125584 million in funding	CI

Avicanna Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 14, 2023 at 05:42 pm EST

Avicanna Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was CAD 6.25 million compared to CAD 0.771263 million a year ago. Net loss was CAD 1.42 million compared to CAD 2.89 million a year ago.
For the nine months, revenue was CAD 10.74 million compared to CAD 2.91 million a year ago. Net loss was CAD 5.69 million compared to CAD 8.19 million a year ago.

Latest news about Avicanna Inc.

Avicanna Raises About $2.1 Million in Non-brokered Private Placement	Apr. 19	MT
Avicanna Inc. announced that it has received CAD 2.125584 million in funding	Apr. 17	CI
Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study	Apr. 10	CI
Transcript : Avicanna Inc., 2023 Earnings Call, Apr 02, 2024	Apr. 02
Avicanna's Q4 Loss Narrows, Revenue Grows	Apr. 02	MT
Avicanna Brief: Reporting $16.8 Million in 2023 Revenue, representing an increase of 314% from 2022	Apr. 02	MT
Avicanna Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Avicanna Announced Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	MT
Avicanna Brief: Announcing Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	MT
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	CI
ThreeD Capital Inc. Announces New YouTube Channel	Mar. 25	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm; Down 5.6%	Feb. 15	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm	Feb. 15	MT
Avicanna Brief: Announcing New Research Collaboration with a Multi-national European-based Pharmaceutical Company	Feb. 15	MT
Avicanna Inc. Announces New Research Collaboration with a Multi-National European-Based Pharmaceutical Company	Feb. 15	CI
Avicanna Brief: Adds Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	Feb. 13	MT
Avicanna Brief: Says Obtained Its First Indication-Specific Drug Registration with Trunerox	Feb. 13	MT
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox	Feb. 13	CI
Avicanna Signs Supply, Licensing Pact With Multinational Pharmaceutical Firm	Feb. 05	MT
Avicanna Inc. Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company	Feb. 05	CI
Avicanna Brief: Also Involves Right of first refusal agreement for the Avicanna's SEDDs capsules in the European region	Feb. 05	MT
Avicanna Brief: Involves Exclusive supply agreement for two of Avicanna's proprietary topical products in the European region	Feb. 05	MT
Avicanna Brief: Announcing Supply and Licensing Agreement with Multinational Pharmaceutical Co	Feb. 05	MT
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil	Jan. 30	MT
Avicanna Brief: Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil	Jan. 30	MT

Chart Avicanna Inc.

Duration

Period

More charts

Company Profile

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patientsâ needs and enhances the patient's journey.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVICANNA INC.	+5.71%	25.67M
IQVIA HOLDINGS INC.	+2.19%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+11.46%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.61%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.06%	18.12B
MEDPACE HOLDINGS, INC.	+30.73%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.44%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.46%	11B

Other Biotechnology & Medical Research